natgillin/translations-raw huggingface dataset:
Leukopenia*, thrombocytopenia*, pancytopenia, agranulocytosis
levkopenija*, trombocitopenija*, pancitopenija, agranulocitoza
Leukopenia, lymph node pain
levkopenija, bolečina v bezgavki
Leukopenia, Neutropenia
levkopenija, nevtropenija
leukopenia, neutropenia, anaemia
levkopenija, nevtropenija, anemija
Leukopenia, neutropenia, and agranulocytosis
Levkopenija, nevtropenija in agranulocitoza
leukopenia, thrombocytope- nia
levkopenija, trombocito- penija
Leukopenia, thrombocytopenia, anaemia
levkopenija, trombocitopenija, anemija
Leukopeniaa
levkopenijaa
Leukopeniaam, thrombocytopeniaam
levkopenijaam, trombocitopenijaam
LeukoScan (0.31 powder for solution for injection) (sulesomab)
LeukoScan (0,31 prašek za raztopino za injiciranje) sulezomaba
LeukoScan 0.31 mg, powder for solution for injection
LeukoScan 0,31 mg prašek za raztopino za injiciranje
LeukoScan 0.31 mg, powder for solution for injection
LeukoScan 0,31 Prašek za raztopino za injiciranje
LeukoScan 0.31 mg, powder for solution for injection sulesomab
LeukoScan 0,31 prašek za raztopino za injiciranje sulezomabu
LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.
Zdravilo LeukoScan ni bilo uporabljeno za diagnosticiranje osteomielitisa pri bolnikih s srpasto celično anemijo.
LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
Zdravilo LeukoScan je indicirano za diagnostično slikanje za določitev mesta in obsega okužbe ali vnetja kosti pri bolnikih, pri katerih obstaja sum na osteomielitis, vključno z bolniki, ki imajo razjede na diabetični nogi.
LeukoScan is not expected to bind to leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Ni pričakovano, da bi se zdravilo LeukoScan vezalo na levkocite bolnikov s paroksizmalno nočno hemoglobinurijo.
LeukoScan is radiolabelled by mixing it with a solution of radioactive technetium (99mTc).
Zdravilo LeukoScan se radioaktivno označi tako, da se zmeša z raztopino radioaktivnega tehnecija (99mTc).
LeukoScan is used to find the site and extent of infection or inflammation in patients with suspected osteomyelitis (bone infection), including patients with diabetic foot ulcers.
Zdravilo LeukoScan se uporablja za odkrivanje mesta in obsega okužbe ali vnetja pri bolnikih, pri katerih obstaja sum, da imajo osteomielitis (okužbo kosti), vključno z bolniki, ki imajo razjede na nogah zaradi sladkorne bolezni.
Leukostasis syndrome
angioedem
Level 1 dose reduction: From 35 mg/m2 to 30 mg/m2
1. raven zmanjšanja odmerka: s 35 mg/m2 na 30 mg/m2
Level 2 dose reduction: From 30 mg/m2 to 25 mg/m2
2. raven zmanjšanja odmerka: s 30 mg/m2 na 25 mg/m2
Level 3 dose reduction: From 25 mg/m2 to 20 mg/m2
3. raven zmanjšanja odmerka: s 25 mg/m2 na 20 mg/m2
level carefully monitored.
nadzirati.
Level of the antibody response (index) for patients without a history of immunosuppressant treatment
Raven odziva protiteles (indeks) za bolnike brez zdravljenja z imunopresivi v anamnezi
Levels of 1,25-dihydroxyvitamin D decreased in Tecfidera treated patients relative to placebo (median percentage decrease from baseline at 2 years of 25% versus 15%, respectively) and levels of parathyroid hormone (PTH) increased in Tecfidera treated patients relative to placebo (median percentage increase from baseline at 2 years of 29% versus 15%, respectively).
Ravni 1,25-dihidroksivitamina D so se pri bolnikih, zdravljenih z zdravilom Tecfidera, v primerjavi z bolniki, ki so prejemali placebo, zmanjšale (mediana odstotka zmanjšanja od izhodiščne vrednosti pri 2 letih 25 % v primerjavi s 15 %), ravni paratiroidnega hormona (PTH) pa so se pri bolnikih, zdravljenih z zdravilom Tecfidera, v primerjavi z bolniki, ki so prejemali placebo, zvišale (mediana odstotka zvišanja od izhodišča pri 2 letih 29 % v primerjavi s 15 %).
Levels of amyloid A were also reduced.
Znižale so se tudi ravni amiloida A.
Levels of approximately 0.2, 0.4, 1.0 and 1.3 IU/mL of anti-Xa were seen in healthy volunteers, following a single subcutaneous administration of 20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg, respectively.
Znaša približno 0,2, 0,4 1,0 in 1,3 i.e./ml anti-Xa po enkratnem subkutanem dajanju odmerkov 20 mg, 40 mg, 1 mg/kg in 1,5 mg/kg zdravim prostovoljcem.
Levels of approximately 0.2, 0.4, 1.0 and 1.3 IU/mL of anti-Xa were seen in healthy volunteers, following a single subcutaneous administration of 20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg, respectively.
Znaša približno 0,2, 0,4 1,0 in 1,3 i.e./ml anti-Xa po enkratnem subkutanem dajanju odmerkov po 20 mg, 40 mg, 1 mg/kg in 1,5 mg/kg zdravim prostovoljcem.
levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA.
protitelesa proti adalimumabu) v serumu manjše pri bolnikih, ki imajo merljivo raven teh protiteles.
levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA.
Ugotovljeno je bilo, da so koncentracije prostega adalimumaba (tiste, ki ni vezan na protitelesa proti adalimumabu) v serumu manjše pri bolnikih, ki imajo merljivo raven teh protiteles.
Levels of HLA- DR (a measure of inflammation in eye cells) were also reduced in patients using Ikervis compared with the dummy treatment.
Prav tako so se pri bolnikih, ki so uporabljali zdravilo Ikervis, v primerjavi s tistimi, ki so prejemali zdravilo brez zdravilne učinkovine, znižale ravni HLA-DR (merilo za oceno vnetja v očesnih celicah).
levels should be monitored when
potrebno nadzorovati
levels2,3
holesterola2,3
levels2,3
ladkorne bolezni,
levels2,5
Zvišane ravni
levels4
glukoze4
levels8
gama
Levemir
zdravilo Levemir
Levemir 100 units/ml
Levemir 100 enot/ml
Levemir 100 units/ml solution for injection in cartridge.
Levemir 100 enot/ml raztopina za injiciranje v injekcijskem vložku
Levemir 100 units/ml solution for injection in pre-filled pen.
Levemir 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Levemir can be used in adolescents and children aged 1 year and above.
Zdravilo Levemir se lahko uporablja pri mladostnikih in otrocih, starih 1 leto in več.
Levemir can be used in older patients.
Zdravilo Levemir lahko uporabite pri starejših bolnikih.
Levemir CV (%)
Zdravilo Levemir CV (%)
Levemir dose adjustment
Prilagoditev odmerka zdravila Levemir
Levemir FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Zdravilo Levemir FlexPen je napolnjen injekcijski peresnik, namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
Levemir FlexPen is a pre-filled, colour-coded, disposable pen containing insulin detemir.
Levemir FlexPen je napolnjen, barvno-kodirani injekcijski peresnik za enkratno uporabo, ki vsebuje insulin detemir.
Levemir FlexPen is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
Barvno kodiranim injekcijskim peresnikom Levemir FlexPen je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Levemir FlexTouch is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Zdravilo Levemir FlexTouch je napolnjen injekcijski peresnik, namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
Levemir FlexTouch is a pre-filled, colour-coded, disposable pen containing insulin detemir.
Levemir FlexTouch je napolnjen, barvno-kodirani injekcijski peresnik za enkratno uporabo, ki vsebuje insulin detemir.
Levemir FlexTouch is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
Barvno kodiranim injekcijskim peresnikom Levemir FlexTouch je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Levemir InnoLet is a pre-filled disposable pen containing insulin detemir.
Levemir InnoLet je napolnjen injekcijski peresnik za enkratno uporabo, ki vsebuje insulin detemir.
Levemir InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Zdravilo Levemir InnoLet je napolnjen injekcijski peresnik, namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
Levemir InnoLet is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilo Levemir InnoLet ima priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Levemir is a soluble, long-acting insulin analogue with a prolonged duration of effect used as a basal insulin.
Zdravilo Levemir je topen dolgodelujoči insulinski analog s podaljšanim delovanjem, ki se uporablja kot bazalni insulin.
Levemir is for subcutaneous administration only.
Zdravilo Levemir je namenjeno zgolj injiciranju pod kožo (subkutani uporabi).
Levemir once daily
Zdravilo Levemir enkrat na dan
Levemir Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilu Levemir Penfill je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Levemir was non-inferior to NPH insulin as measured by HbA1c at gestational week (GW) 36, and the reduction in mean HbA1c through pregnancy was similar, see table 4.
Zdravilo Levemir je bilo enakovredno insulinu NPH, merjeno s HbA1c v 36. tednu nosečnosti (TN), in znižanje povprečnega HbA1c med nosečnostjo je bilo podobno (glejte
Levemir was studied in an open-label randomised controlled clinical trial pregnant women with type 1 diabetes (n=310) were treated in a basal-bolus treatment regimen with Levemir (n=152) or NPH insulin (n=158) as basal insulin, both in combination with NovoRapid (see section 4.6).
V odprtem, randomiziranem, kontroliranem kliničnem preskušanju so nosečnice s sladkorno boleznijo tipa 1 (n = 310) zdravili z bazalno-bolusno shemo, v kateri je bil bazalni insulin bodisi zdravilo Levemir (n = 152) bodisi insulin NPH (n = 158), oba v kombinaciji z zdravilom NovoRapid (glejte poglavje 4.6).
Levemir was the basal insulin product for 33% (N = 147) of the patients (97.3% using metformin).
Zdravilo Levemir je bil bazalni insulin pri 33 % (N = 147) vseh bolnikov (97,3 % bolnikov je uporabljalo tudi metformin).
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam v odmerku 1.000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam v odmerku 1000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam v odmerku 1.000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
Levetiracetam 100mg/ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50 kg and when tablets don’t allow accurate dosage.
Za dojenčke in otroke, mlajše od 6 let, otroke in mladostnike (od 6 do 17 let), lažje od 50 kg, ter kadar se s tabletami ne doseže natančnega odmerjanja, je 100 mg/ml peroralna raztopina levetiracetama primernejša farmacevtska oblika.
Levetiracetam Accord 1000 mg
Levetiracetam Accord 1.000 mg
Levetiracetam Accord 1000 mg film-coated tablets
Levetiracetam Accord 1.000 mg filmsko obložene tablete
Levetiracetam Accord 1000 mg film-coated tablets Levetiracetam
Levetiracetam Accord 1.000 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 250 mg film-coated tablet Levetiracetam
Levetiracetam Accord 250 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 250 mg film-coated tablets
Levetiracetam Accord 250 mg filmsko obložene tablete
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets Levetiracetam
Levetiracetam Accord 250 mg filmsko obložene tablete Levetiracetam Accord 500 mg filmsko obložene tablete Levetiracetam Accord 750 mg filmsko obložene tablete Levetiracetam Accord 1.000 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 500 mg film-coated tablet Levetiracetam
Levetiracetam Accord 500 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 500 mg film-coated tablets
Levetiracetam Accord 500 mg filmsko obložene tablete
Levetiracetam Accord 500 mg film-coated tablets Levetiracetam
Levetiracetam Accord 500 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 750 mg film-coated tablet contains sunset yellow FCF (E110) colouring agent which may cause allergic reactions.
Zdravilo Levetiracetam Accord 750 mg filmsko obložene tablete vsebujejo oranžno barvilo FCF (E110), ki lahko povzroči alergijske reakcije.
Levetiracetam Accord 750 mg film-coated tablet Levetiracetam
Levetiracetam Accord 750 mg filmsko obložene tablete levetiracetam
Levetiracetam Accord 750 mg film-coated tablets
Levetiracetam Accord 750 mg filmsko obložene tablete
Levetiracetam Accord film-coated tablets 250 mg, 500 mg, 750 mg and 1000 mg are packed in PVC-Alu blister pack.
Levetiracetam Accord filmsko obložene tablete 250 mg, 500 mg, 750 mg in 1.000 mg so pakirane v PVC-Alu pretisne omote.
Levetiracetam Accord has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Študije na živalih so pri odmerkih zdravila Levetiracetam Accord, ki so višji kot je potrebno za nadzor napadov, pokazale neželene učinke na razmnoževanje.
Levetiracetam Accord is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).
Levetiracetam Accord je zdravilo proti epilepsiji (zdravilo za zdravljenje epileptičnih napadov).
Levetiracetam Accord is not indicated in children and adolescents below 16 years on its own (monotherapy).
Zdravilo Levetiracetam Accord pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
Levetiracetam Accord is used
Zdravilo Levetiracetam Accord se uporablja:
Levetiracetam Accord is used as a chronic treatment.
Zdravilo Levetiracetam Accord se uporablja za dolgotrajno zdravljenje.
Levetiracetam Accord may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Zdravilo Levetiracetam Accord lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali stroji, saj lahko povzroči zaspanost.
Levetiracetam Accord should not be used during pregnancy unless clearly necessary.
Zdravila Levetiracetam Accord med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Levetiracetam Actavis 1,000 mg tablets are oval, white, 19.0 x 10.0 mm marked with “L” on one side and “1000” on the other side.
Levetiracetam Actavis 1000 mg filmsko obložene tablete so: ovalne, bele, velike 19.0 x 10.0 mm z oznako “L” na eni strani in “1000”na drugi strain
Levetiracetam Actavis 250 mg film-coated tablets are oval, light blue, 13.6 x 6.4 mm marked with “L” on one side and “250” on the other side.
Levetiracetam Actavis 250 mg filmsko obložene tablete so: ovalne, svetlo modre, velike 13.6 x 6.4 mm z oznako “L” na eni strani in “250” na drugi strani.
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1,000 mg film-coated tablets
Levetiracetam Actavis 250 mg filmsko obložene tablete Levetiracetam Actavis 500 mg filmsko obložene tablete Levetiracetam Actavis 750 mg filmsko obložene tablete Levetiracetam Actavis 1000 mg filmsko obložene tablete
Levetiracetam Actavis 250 mg, 500 mg and 1,000 mg film-coated tablets
Levetiracetam Actavis 250 mg, 500 mg in 1.000 mg filmsko obložene tablete
Levetiracetam Actavis 500 mg tablets are oval, yellow, 17.1 x 8.1 mm marked with “L” on one side and “500” on the other side.
Levetiracetam Actavis 500 mg filmsko obložene tablete so: ovalne, rumene, velike 17.1 x 8.1 mm z oznako “L” na eni strani in “500” na drugi strani.
Levetiracetam Actavis 750 mg tablets are oval, orange, 19.0 x 9.3 mm marked with “L” on one side and “750” on the other side.
Levetiracetam Actavis 750 mg filmsko obložene tablete so: ovalne, oranžne, velike 19.0 x 9.3 mm z oznako “L” na eni strani in “750” na drugi strani.
Levetiracetam Actavis Group is a ‘generic medicine’.
Levetiracetam Actavis Group je „generično zdravilo“.
Levetiracetam Actavis is indicated as adjunctive therapy
Zdravilo Levetiracetam Actavis je indicirano za dopolnilno zdravljenje
Levetiracetam Actavis is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Zdravila Levetiracetam Actavis med nosečnostjo in pri ženskah v rodni dobi, brez kontracepcije ni priporočljivo uporabljati, razen če je to klinično potrebno.
Levetiracetam Actavis is used as a chronic treatment.
Zdravilo Levetiracetam Actavis se uporablja za kronično zdravljenje.
Levetiracetam Actavis is used:
Zdravilo Levetiracetam Actavis se uporablja:
Levetiracetam Actavis should not be used during pregnancy unless clearly necessary.
Zdravila Levetiracetam Actavis med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Levetiracetam has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Študije na živalih so pri odmerkih levetiracetama, ki so višji kot je potrebno za nadzor napadov, pokazale neželene učinke na reprodukcijo.
Levetiracetam Hospira 100 mg/ml concentrate for solution for infusion Levetiracetam
Levetiracetam Hospira 100 mg/ml koncentrat za raztopino za infundiranje levetiracetam
Levetiracetam Hospira concentrate for solution for infusion is an alternative for patients when administration of the antiepileptic levetiracetam medicine by mouth is temporarily not feasible.
Zdravilo Levetiracetam Hospira koncentrat je alternativa za bolnike, ko uporaba peroralnega protiepileptičnega zdravila z levetiracetamom začasno ni mogoča.
Levetiracetam Hospira contains sodium
Zdravilo Levetiracetam Hospira vsebuje natrij
Levetiracetam Hospira is not indicated in children and adolescents below 16 years on it’s own (monotherapy)
zdravilo Levetiracetam Hospira pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
Levetiracetam Hospira is used:
Zdravilo Levetiracetam Hospira se uporablja:
Levetiracetam Hospira should not be used during pregnancy unless clearly necessary.
Zdravila Levetiracetam Hospira med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Levetiracetama med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije, ni priporočljivo uporabljati, razen če ni klinično potrebno.
Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Levetiracetama ne uporabljajte pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije, razen če ni klinično potrebno.
Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Zdravila Levetiracetam med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije, ni priporočljivo uporabljati, razen če ni klinično potrebno.
Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation).
Levetiracetam se uporablja za obliko epilepsije, pri kateri napadi najprej vplivajo le na eno stran možganov, vendar se lahko kasneje razširijo na večjo površino na obeh straneh (parcialni napadi s sekundarno generalizacijo ali brez nje).
Levetiracetam oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Pri dojenčkih in otrocih, mlajših od 6 let je najprimernejša farmacevtska oblika za uporabo levetiracetama peroralna raztopina.
Levetiracetam ratiopharm 100 mg/ml oral solution
Levetiracetam ratiopharm 100 mg/ml peoralna razopina
Levetiracetam ratiopharm 100 mg/ml oral solution contains methyl parahydroxybenzoate (E 218) and propyl parahydroxybenzoate (E 216) which may cause allergic reactions (possibly delayed).
Zdravilo Levetiracetam ratiopharm 100 mg/ml peroralna raztopina vsebuje metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216), ki lahko povzročata alergijske reakcije (lahko so zakasnele).
Levetiracetam ratiopharm 100 mg/ml oral solution For children aged 1 month to less than 6 months.
Levetiracetam ratiopharm 100 mg/ml peroralna raztopina Za otroke, stare od 1 meseca do manj kot 6 mesecev.
Levetiracetam ratiopharm 100 mg/ml oral solution For children between 1 and 6 months.
Levetiracetam ratiopharm 100 mg/ml peroralna raztopina Za otroke, stare od 1 meseca do manj kot 6 mesecev.
Levetiracetam ratiopharm 100 mg/ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescent (from 6 to 17 years) weighing less than 50 kg and when tablets don’t allow accurate dosage.
Za dojenčke in otroke, mlajše od 6 let, za otroke in mladostnike (od 6 do 17 let), težke manj kot 50 kg in kadar s tabletami ne moremo zagotoviti natančnega odmerjanja, je zdravilo Levetiracetam ratiopharm 100 mg/ml peroralna raztopina primernejša farmacevtska oblika.
Levetiracetam ratiopharm 100 mg/ml oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Farmacevtska oblika peroralna raztopina zdravila Levetiracetam ratiopharm 100 mg/ml je najprimernejša za uporabo pri dojenčkih in otrocih, mlajših od 6 let.
Levetiracetam ratiopharm 100 mg/ml oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Tablete niso primerne za zdravljenje dojenčkov in otrok, starih manj kot 6 let, ampak se pri tej populaciji priporoča uporaba peroralne raztopine zdravila Levetiracetam ratiopharm 100 mg/ml.
Levetiracetam ratiopharm 1000 mg
Zdravilo Levetiracetam ratiopharm 1000 mg
Levetiracetam ratiopharm 250 mg
Zdravilo Levetiracetam ratiopharm 250 mg
Levetiracetam ratiopharm 500 mg
Zdravilo Levetiracetam ratiopharm 500 mg
Levetiracetam ratiopharm 500 mg film-coated tablets EU/1/11/702/010
Levetiracetam ratiopharm 500 mg filmsko obložene tablete EU/1/11/702/010
Levetiracetam ratiopharm 750 mg
Zdravilo Levetiracetam ratiopharm 750 mg
Levetiracetam ratiopharm contains methyl parahydroxybenzoate, propyl parahydroxybenzoate and potassium
Zdravilo Levetiracetam ratiopharm vsebuje metilparahidroksibenzoat, propilparahidroksibenzoat in kalij
Levetiracetam ratiopharm has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Študije na živalih so pri odmerkih zdravila Levetiracetam ratiopharm, ki so višji kot je potrebno za nadzor napadov, pokazale neželene učinke na razmnoževanje.
Levetiracetam ratiopharm is used as a chronic treatment.
Zdravilo Levetiracetam ratiopharm se uporablja za kronično zdravljenje.
Levetiracetam ratiopharm is used:
Zdravilo Levetiracetam ratiopharm se uporablja: